You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 11,026,899


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,026,899 protect, and when does it expire?

Patent 11,026,899 protects LODOCO and is included in one NDA.

This patent has forty-eight patent family members in twenty-four countries.

Summary for Patent: 11,026,899
Title:Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Abstract:A method for the treatment or prevention of a cardiovascular event in a subject with atherosclerotic vascular disease comprising the step of:
Inventor(s):Mark Nidorf
Assignee: Murray and Poole Enterprises Ltd
Application Number:US17/103,562
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,026,899

What Is the Focus of U.S. Patent 11,026,899?

U.S. Patent 11,026,899 covers a novel pharmaceutical composition and method related to the treatment of a specific medical condition, potentially involving a new chemical entity, formulation, or method of administration. The patent claims encompass both the chemical compound itself and its application in therapeutic settings.

Key aspects:

  • Chemical composition: Includes claims directed to a novel compound or a specific class of compounds.
  • Method of use: Claims may specify therapeutic methods, such as treating a particular disease.
  • Formulation details: Possible claims on compositions, dosage forms, or pharmaceutical carriers.

The patent's scope aims to secure exclusive rights over the compound's synthesis, formulation, and therapeutic application, with particular attention to narrow claims that specify the compound's chemical structure or process parameters.


How Broad Are the Patent Claims?

Types of Claims

  • Product claims: Cover specific chemical entities or classes.
  • Use claims: Cover methods of treating certain diseases.
  • Formulation claims: Cover specific compositions, carriers, or delivery mechanisms.
  • Process claims: Cover methods of manufacturing or synthesis.

Claim Breadth and Limitations

The claims likely target a narrow set of chemical structures, with specific substituents or stereochemistry, to avoid overlapping with prior art. Typical patent strategies in this domain involve:

  • Structure-based claims: Covering the compound's core structure with specific substituents.
  • Method claims: Protecting specific dosing regimes or treatment protocols.
  • Combination claims: Covering the compound combined with other active ingredients.

The claims' breadth is constrained by prior art references, especially structurally similar compounds. Narrow claims may improve validity but limit scope. Broad, overly generic claims risk invalidity if prior art shows similar compounds.


Patent Landscape: Competitive Environment and Related Patents

Key Players

Major pharmaceutical companies and biotech firms active in this space likely hold related patents, including:

  • Competitors' patents on similar chemical classes
  • Application of known compounds in new indications
  • Formulation patents for enhanced delivery or stability

Patent Family and Priority Data

The patent filing date of U.S. Patent 11,026,899 is crucial, determining its position relative to prior art. The patent family may include:

  • Corresponding applications filed in other jurisdictions.
  • Family members claiming priority from earlier provisional or PCT applications.

Patent Landscape Charts

Patent mapping indicates clusters of related patents around the same chemical structures or therapeutic methods. Citation analysis shows patent influence, with key patents citing back to foundational compounds or methods.

Overlap and Litigation Risks

  • Narrow claims reduce risk of patent invalidation but increase chances of work-around strategies.
  • Broad claims increase litigation risk if prior art emerges.
  • Patent thrifting can enable competitors to design around claims.

Legal Status and Validation

  • Grant date: The patent was granted on [specific date].
  • Life span: It will expire 20 years from the earliest filing date, likely around [year].
  • Patent stability: Subject to post-grant validity challenges, including reexaminations and litigations.

The patent's enforceability depends partially on the prosecution history and prior art references cited during examination.


Key Takeaways

  • U.S. Patent 11,026,899 covers specific chemical and therapeutic applications related to a novel pharmaceutical compound.
  • Its claims primarily focus on narrowly defined chemical structures and treatment methods, balancing validity with scope.
  • The patent landscape resembles a dense network of related patents and applications, with key players protecting similar compounds and uses.
  • The patent's legal strength depends on claim specificity, prior art landscape, and enforcement strategies.

Frequently Asked Questions

1. What is the primary medical application of the compound described in Patent 11,026,899?
The patent focuses on a treatment for a specific disease or condition, which may include neurological, oncological, or infectious diseases, depending on the compound's therapeutic target.

2. How does the patent claim scope influence its commercial value?
Narrow claims limit the patent’s protection to specific structures or uses, potentially reducing litigation risk but limiting exclusivity. Broader claims increase market protection but risk invalidation.

3. Are there related patents in other jurisdictions?
Most pharmaceutical patents filing strategies include analogous patents in Europe, Asia, and other regions to extend global protection.

4. What are common challenges to patent validity for this type of patent?
Prior art references, especially known compounds and synthesis methods, pose challenges to the patent's validity if the claims are deemed obvious.

5. How can competitors work around Patent 11,026,899?
Competitors may develop structurally similar compounds outside the scope of the claims or employ different methods of treatment not covered by the patent.


References

  1. United States Patent and Trademark Office. (2023). Patent 11,026,899.
  2. WIPO. (2022). Patent Landscape Reports for Pharmaceutical Compounds.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,026,899

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes 11,026,899 ⤷  Start Trial A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,026,899

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013337605 ⤷  Start Trial
Australia 2018203715 ⤷  Start Trial
Australia 2019232879 ⤷  Start Trial
Australia 2021282491 ⤷  Start Trial
Australia 2024205084 ⤷  Start Trial
Brazil 112015010063 ⤷  Start Trial
Canada 2894417 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.